|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Skin and Soft Tissue Infections
Datamonitor, July 2009, Pages: 94
Treatment of skin and skin structure infections often requires systemic antibacterial therapy. Two trends are concerning physicians: the spread of methicillin-resistant Staphylococcus aureus (MRSA), particularly community-acquired strains (CA-MRSA) have become the most important pathogen in the US; and a slow but measurably declining susceptibility to vancomycin by these bacteria.
Scope
- Epidemiological trends and economic impact of key pathogens
- Overview of diagnosis and referral patterns
- Analysis of present and future unmet needs with outline of key drugs in development for SSTIs
- Outline of drivers of treatment choice in both the hospital and the community setting
Highlights of this title
Guideline adoption for skin and soft tissue infections (SSTIs) among specialists is fairly strong, but less so among primary care physicians (PCPs). PCPs treat mild-to-moderate forms of disease, representing an estimated 70% of SSTI patients, while specialists treat severe SSTI sufferers (30%).
Resistance is the single most important factor affecting the SSTI drug market, in both the community and hospital settings. Vancomycin has traditionally been viewed as the most effective treatment option for SSTIs caused by MRSA, although bacterial resistance to the drug is emerging and it is becoming less effective for the treatment of SSTIs.
A highly valuable new SSTI drug should possess a number of important characteristics, including strong bactericidal activity against MRSA, VISA, and H-VISA strains, a good toxicity and side effect profile, cost-effectiveness, good tissue penetration for systemic use, superior efficacy versus vancomycin, and broad spectrum coverage.
Key reasons to purchase this title
- Identify key opportunities that will impact the use and uptake of new and existing products
- Understand the critical issues that drive prescription choice in skin and soft tissue infections
- Learn about the difference between key antibacterial drug attributes relevant to hospital and community-based physicians
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?
Stakeholder Opinions: Nosocomial Infections - The Need for New Gram-negative Drugs
Bacterial Infections: An Epidemiological Overview
Bacterial Infections: An Epidemiological Overview
Identifying Drug-Resistant Bacterial Infections: Opportunity and Activity in the Diagnostics Arena
Urinary Tract Infections: Growing Resistance Rates bring Opportunities for Both New and Old Drugs
Infections and Wound Treatments
Commercial & Pipeline Insight: Hospital Antibacterials A market beyond MRSA
Drugs of Tomorrow 2001: Bacterial Infections
Dermatology - Skin Infections or Dermatosis or Skin Itching Drug Pipeline Report
Antibiotics and Drug Resistance
Tissue Sealants
|
|
|
|
